Metsera, Inc.

Compare

169 Followers

MTSR Stock Chart & Stats

$52.21

Market closed

$52.21

Day’s Range― - ―

52-Week Range$12.30 - $54.47

Previous CloseN/A

VolumeN/A

Average Volume (3M)2.70M

Market Cap

$5.50B

Enterprise Value$2.45B

Total Cash (Recent Filing)$530.92M

Total Debt (Recent Filing)$1.06M

Price to Earnings (P/E)―

Beta1.46

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding105,292,750

10 Day Avg. Volume657,933

30 Day Avg. Volume2,698,571

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)9.69

Price to Sales (P/S)0.00

P/FCF Ratio-27.82

Enterprise Value/Market Cap0.45

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-204.55K

Enterprise Value/Ebitda-8.84

Forecast

1Y Price Target

$55.33

Price Target Upside5.98% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressFaster-than-expected enrollment in clinical trials is seen as a positive sign for MTSR's clinical trial execution.

Experienced LeadershipThe company is led by highly experienced executives with strong track records.

Therapeutics AdvantageThe company's platform and pipeline of novel obesity peptide-based therapeutics offer key advantages relative to competing assets.

Bears Say

Metsera, Inc. News

M&A War: Pfizer Blasts Rival Novo Nordisk for “Reckless” $8.5B Hijack of Metsera Obesity Deal

Danish drug giant Novo Nordisk ($NVO) has been accused by rival Pfizer ($PFE) of being “reckless” after it...

6m ago

NVO

PFE

Metsera receives unsolicted proposal from Novo Nordisk

07:10 EDT Metsera (MTSR) receives unsolicted proposal from Novo Nordisk (NVO) Published first on TheFly – the ultimate...

55m ago

NVO

PFE

Novo Nordisk offers to buy Metsera for up to $77.75 per share, or $9B

Metsera (MTSR) announced that its Board of Directors had determined, after consultation with its outside counsel and financial...

56m ago

NVO

PFE

Metsera declares Novo Nordisk proposal ‘superior’

07:12 EDT Metsera (MTSR) declares Novo Nordisk (NVO) proposal ‘superior’ Published first on TheFly – the ultimate source...

56m ago

NVO

PFE

Pfizer addresses proposal for Metsera

“Pfizer (PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NVO) to acquire Metsera...

1h ago

NVO

PFE

Metsera Considers Novo Nordisk’s Superior Proposal

Metsera, Inc. ( ($MTSR) ) just unveiled an announcement. On October 29, 2025, Metsera, Inc. announced that its...

14m ago

MTSR

Metsera’s MET233 Study: A Potential Game-Changer in Obesity Treatment

Metsera, Inc. (($MTSR)) announced an update on their ongoing clinical study. Study Overview: Metsera, Inc. is conducting a...

3d ago

MTSR

Metsera’s New Phase 1 Study: A Potential Game-Changer in Obesity Treatment

Metsera, Inc. (($MTSR)) announced an update on their ongoing clinical study. Study Overview: Metsera, Inc. (MTSR) is conducting...

3d ago

MTSR

Metsera’s MET097 Study: A Potential Game-Changer in Obesity and Diabetes Treatment

Metsera, Inc. (($MTSR)) announced an update on their ongoing clinical study. Study Overview: Metsera, Inc. is conducting a...

3d ago

MTSR

Metsera, Inc. Announces Special Meeting for Merger Vote with Pfizer

New activity is brewing for Metsera, Inc. ( ($MTSR) ). The company has submitted a Form DEFM14A to...

13d ago

MTSR

Metsera Announces Positive Phase 2b Trial Results

The latest announcement is out from Metsera, Inc. ( ($MTSR) ). On September 29, 2025, Metsera, Inc. announced...

1M ago

MTSR

Metsera downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo analyst Cerena Chen downgraded Metsera (MTSR) to Equal Weight from Overweight with a price target of...

1M ago

PFE

MTSR

Metsera reports ‘positive’ Phase 2b results for GLP-1 RA candidate MET-097i

Metsera (MTSR) announced positive topline data from VESPER-1 and positive data from a planned interim analysis for tolerability...

1M ago

MTSR

Metsera downgraded to Market Perform from Outperform at Leerink

Leerink downgraded Metsera (MTSR) to Market Perform from Outperform with a price target of $57, down from $77,...

1M ago

MTSR

MTSR FAQ

What was Metsera, Inc.’s price range in the past 12 months?

Metsera, Inc. lowest stock price was $12.30 and its highest was $54.47 in the past 12 months.

What is Metsera, Inc.’s market cap?

Metsera, Inc.’s market cap is $5.50B.

When is Metsera, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Metsera, Inc.’s earnings last quarter?

Metsera, Inc. released its earnings results on May 12, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.945 by -$0.085.

Is Metsera, Inc. overvalued?

According to Wall Street analysts Metsera, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Metsera, Inc. pay dividends?

Metsera, Inc. does not currently pay dividends.

What is Metsera, Inc.’s EPS estimate?

Metsera, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Metsera, Inc. have?

Metsera, Inc. has 105,292,750 shares outstanding.

What happened to Metsera, Inc.’s price movement after its last earnings report?

Metsera, Inc. reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.945. Following the earnings report the stock price went down -5.732%.

Which hedge fund is a major shareholder of Metsera, Inc.?

Currently, no hedge funds are holding shares in MTSR

Metsera, Inc. Stock Smart Score

Neutral

Company Description

Metsera, Inc.

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.

Metsera, Inc. (MTSR) Earnings & Revenues

Historic Earnings Reports

MTSR Stock 12 Month Forecast

Average Price Target

$55.33

▲(5.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","63":"$63","32.25":"$32.3","42.5":"$42.5","52.75":"$52.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$62.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$55.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,32.25,42.5,52.75,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.12,52.879999999999995,53.64,54.4,55.16,55.92,56.68,57.44,58.2,58.96,59.72,60.480000000000004,61.24,{"y":62,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.12,52.36692307692307,52.613846153846154,52.86076923076923,53.107692307692304,53.354615384615386,53.60153846153846,53.848461538461535,54.09538461538461,54.34230769230769,54.58923076923077,54.83615384615384,55.08307692307692,{"y":55.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.12,51.956923076923076,51.793846153846154,51.63076923076923,51.4676923076923,51.30461538461538,51.14153846153846,50.97846153846154,50.815384615384616,50.652307692307694,50.489230769230765,50.326153846153844,50.16307692307692,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.8,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >